year 14, Issue 4 (July - August 2020)                   Iran J Med Microbiol 2020, 14(4): 348-360 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Miandehi N, bidoki K, Ajorloo M, Gholami A. Change in the Basic Structure of the Rabies Virus Glycoprotein by Reverse Genetics. Iran J Med Microbiol 2020; 14 (4) :348-360
URL: http://ijmm.ir/article-1-1098-en.html
1- Department of Biology, Payam-e Noor University, Tehran, Iran
2- Department of Biology, Payame Noor University, Tehran, Iran
3- Department of Clinical Laboratory Sciences, School of Allied Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
4- The National Center for Reference and Research on Rabies, Virology Department, Pasteur Institute of Iran, Tehran, Iran , a.gholami@pasteur.ac.ir
Full-Text [PDF 1382 kb]   (1506 Downloads)     |   Abstract (HTML)  (3978 Views)
Full-Text:   (1193 Views)
Introduction

.

Rabies is a deadly zoonotic disease caused by rabies virus, spread around the world and can infect all mammals, including humans. The virus infects the central nervous system and leads to disorders in central nervous system (1), with horrible and acute neurological symptoms in the clinical stage. The rabies virus belongs to the rhabdovirus family and lyssavirus genus. Their genetic material is a single-stranded RNA with a negative polarity and a length of about 12kb. The genome of virus encodes five proteins (N, P, M, G, and L) (2). The G protein (glycoprotein) binds to some specific cell’s receptors and also provokes immune response against the virus in the host. Antigenic sites on G protein are essential roles in this regard. The antigenic site I carries linear and three-dimensional epitopes located between226-231 amino acid residues. Another major antigenic site II is located between the amino acids 34-42 (II_b) and 198-200 (II_a). The main antigenic site III is a continuous epitope located between the amino acids 330-338.Epitope IV consists of only one amino acid at position 251. The G1 (also called the antigenic site a) and G5 sub-antigenic sites are also in positions 342-343 and 261-264, respectively (3) (Figure 1).

 
Figure 1. Schematic view of the glycoprotein structure of rabies virus. The main antigenic sites and the location of the amino acids associated with them. 
Figure 1. Schematic view of the glycoprotein structure of rabies virus. The main antigenic sites and the location of the amino acids associated with them.
 

The virus enters the cell via the endocytic pathway, and its replication and propagation cycle is entirely cytoplasmic (5). Once the virus genome is released into the cytoplasm, its genome is used as mRNA to express viral proteins genes, as well as to synthesisantigenome (positive polarity) in order to amplify the virus genome. The rabies virus polymerase complex is consisted of phosphoprotein and the polymerase protein (P and L respectively), which is responsible for transcription and replication of the virus genome (6). According to the above, in the construction of the recombinant rabies virus with reverse genetic technology, only N, P, and L proteins are necessary to form the virus-producing devices. Reverse genetics is a type of technology that manipulates and makes genetic changes in an organism in order to study the altered phenotype in the organism (7).In order to rescue a recombinant and active RNA virus, the cDNA clone from the virus should be prepared and converted into an RNA molecule inside the host cell (9).Genetic modification of the rabies virus toward improving its immunogenicity is one of the valuable applications of this technology. Accordingly, with the aim of establishing a suitable basis for this method in the country and using it in future research, genetic modification in the glycoprotein of rabies virus was done and its release of the active virus particle from the cell was shown.

 

Materials and Methods

Design and Manufacture of Mutated Glycoprotein
The genetic sequence of the rabies virus glycoprotein strain of Pasteur virus (PV) was obtained from the NCBI database. To generate the desired genetic mutation, the Mega4 software was used to change the genetic code from glycine (GGG) to glutamic acid (GAG) at the main antigenic site II_b, amino acid number 40.

Insertion of Mutated Glycoprotein into the Expression Vector
The mutated glycoprotein-carrying plasmid of the rabies virus was cut by the two restricted enzymes Nco I and SnaB I (Thermo Fisher) and the glycoprotein gene was removed and replaced in the expressing construct of the rabies virus (PV strain) genome instead of the original gene. After cloning in the Top 10 bacteria, PCR was performed and send to gene sequencing.

Animal Cell Culture
After transfection of the T7-BHK cell with expression vectors of N,P, L and modified G genes by lipofectamin 2000 (Invitrogen), the recombinant virus was rescued and inoculated to the BSR (Baby Syrian Related) cells.

Confirmation of Mutant Virus Sequence After Recovery
In order to compare the sequence of the mutated virus with other samples studied in this study, the cells of which were collected and RNA extraction was performed. cDNA was made from extracted RNA. The glycoprotein gene was then multiplied using PCR and specific primers and the PCR product was sent for sequencing.


 

Results
Confirmation of the Mutated Glycoprotein Gene Sequence in the Expression Vector
Mutated glycoprotein gene was transferred into the construct expressing the genome of the rabies virus by two restriction enzymes. The new cloned gene was generated by suitable PCR primers (Figure 2).
 
Transfected T7-BHK Cell by Expression Plasmids Containing Virus Genes
The expression genes are depended on the T7-RNA polymerase promoter, produced in this cells. To ensure the correct function of the cells in polymerase expression, the cells were transfected with 4T7A construct and their presence of eGFP protein in microscopic evaluation was well confirmed (Figure 3).Transfection of the above cells with full genomes and expression constructs of virus (N, P, and L) confirmed the expression of viral proteins in T7-BHK cells after specific staining (Figure 4).
 
Figure 2. The PCR result on the mutated glycoprotein gene after cloning it into the expression vector. 1 kb marker (A), mutated glycoprotein gene (B), weight marker pattern used (C).
Figure 2. The PCR result on the mutated glycoprotein gene after cloning it into the expression vector. 1 kb marker (A), mutated glycoprotein gene (B), weight marker pattern used (C).
 
    Figure 3. T7-BHK cells transfection results. T7-BHK cells (right), T7-BHK cells transfected with 4T7A structure to confirm T7 polymerase function (middle), the negative control cells with immunofluorescence staining (left).
Figure 3. T7-BHK cells transfection results. T7-BHK cells (right), T7-BHK cells transfected with 4T7A structure to confirm T7 polymerase function (middle), the negative control cells with immunofluorescence staining (left).
 
 Figure 4. T7BHK cell transfected with expression plasmids. The cell containing the virus genome, with the expression vectors containing the L, P, and N genes of immunofluorescence staining with specific antibodies, shows the production of viral proteins (left). Negative control cells transfected with the same plasmids except L (right).
Figure 4. T7BHK cell transfected with expression plasmids. The cell containing the virus genome, with the expression vectors containing the L, P, and N genes of immunofluorescence staining with specific antibodies, shows the production of viral proteins (left). Negative control cells transfected with the same plasmids except L (right).
 
Infectivity of Recovered Viruses in the BSR Cells
Microscopic observation of BSR cells after specific staining confirmed the ability of virus to infect the cells. It was also observed that the infectivity of the recovered virus improved during subsequent passages (Figure 5). RNA extraction was performed from the virus produced in the BSR cell and sequencing of the virus glycoprotein gene confirmed the presence of a mutation in the recovered virus (Figure 6).

 

Figure 5. Increasing the virus's ability to infect during consecutive cultures: The left side of the virus-infected cells in the first passage of the virus, compared to the cells infected in the second passage of the virus (right).
Figure 5. Increasing the virus's ability to infect during consecutive cultures: The left side of the virus-infected cells in the first passage of the virus, compared to the cells infected in the second passage of the virus (right).
 
Figure 6. Determination of glycoprotein sequence of non-mutated recovered virus (Rescued PV), control vaccine strain (PV) virus, mutated recovered virus (Rescued Modified PV). The location of the mutated nucleotide is shown in the figure with the arrow. 
Figure 6. Determination of glycoprotein sequence of non-mutated recovered virus (Rescued PV), control vaccine strain (PV) virus, mutated recovered virus (Rescued Modified PV). The location of the mutated nucleotide is shown in the figure with the arrow.

 

 

Discussion

In this study, using genetic engineering methods, molecular changes were created in the glycoprotein of rabies virus and the recombinant virus recovered. The virus has shown the ability to infect animal cell culture. In 2003, Nauto Ito et al. improved the recovery of rabies virus from cloned cDNA using reverse genetics without the vaccinia auxiliary virus (18). In the present study, the recombinant rabies virus was recovered using a similar system, the desired change in glycoprotein gene was first altered and then transfected to T7-BHK cell with others viral proteins encoding genes. Rabies virus glycoprotein (RVGP) is the main antigen of the virus and is the only viral component of all new rabies vaccines available. Many new methods have been used since recombinant DNA technology became available for the expression of recombinant immunogenic viral glycoproteins (rRVGP). Recent studies on the development of rabies vaccines have focused on the expression of rRVGP in vivo by transferring the viral vectors into the body. This method is considered as the basis of biotechnology for the new generation of rabies vaccines (27).


 

Conclusion

In this study, we tried to rescue the rabies virus by modifying  the structure of the protein  that is effective in the antigenicity and immunogenicity, so that it could be used in qualitative and quantitative tests required for rabies vaccine.
 

Acknowledgements

This work was supported by the production and research complex of Pasteur Institute of Iran. Human rabies vaccine production department.
 

 
Conflicts of Interest

Authors declared no conflict of interests.
 

Type of Study: Original Research Article | Subject: Medical Virology
Received: 2020/04/5 | Accepted: 2020/06/2 | ePublished: 2020/07/20

References
1. Sudhi Ranjan Garg, Rabies in Man and Animals, Springer India, 2014.
2. Rabies - epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review. Veterinary quarterly, 2017 VOL. 37, NO. 1, 212-251 [DOI:10.1080/01652176.2017.1343516] [PMID]
3. Kuzmina et al., Conservation of Binding Epitopes for Monoclonal Antibodies on the Rabies Virus Glycoprotein. J Antivir Antiretrovir 2013, 5:2. [DOI:10.4172/jaa.1000061]
4. Lihong Tao et al., Molecular Basis of Neurovirulence of Flury Rabies Virus Vaccine Strains: Importance of the Polymerase and the Glycoprotein R333Q Mutation. Journal of Virology. 2010, 9; 84, (17):8926-8936 [DOI:10.1128/JVI.00787-10] [PMID] [PMCID]
5. Le Blanc et al, Endosome-to-cytosol transport of viral nucleocapsids. Nature Cell Biology, (2005). 7(7), 653-664. [DOI:10.1038/ncb1269] [PMID] [PMCID]
6. Andrés Ross B. et al, Rabies virus glycoprotein: structure, immunogenicity and role in pathogenesis. Rev Chil Infect. 2008; 25 (Suppl):S 14-S 18
7. Kibruyesfa Bayou, Current Techniques and Applications of Reverse Genetics: An overview. International Journal of Genetics. 2017, 7(2): 31-37.
8. Christopher C. Stobart and Martin L. Moore. RNA virus Reverse Genetics and Vaccine Design. Review, Viruses 2014, 6: 2531-2550. [DOI:10.3390/v6072531] [PMID] [PMCID]
9. Radecke F, Spielhofer P, et al. Rescue of measles viruses from cloned DNA. EMBO J. 1995; 14(23):5773-84. [DOI:10.1002/j.1460-2075.1995.tb00266.x] [PMID] [PMCID]
10. Taniguchi T, Palmieri M, Weissmann C. Qβ DNA-containing hybrid plasmids giving rise to Qβ phage formation in the bacterial host. Nature. 1978; 274:223-8. [DOI:10.1038/274223a0] [PMID]
11. Luytjes W, Krystal M, Enami M, Parvin J, Palese P. Amplification, expression, and packaging of a foreign gene by influenza virus. Cell. 1989; 59:1107-13. [DOI:10.1016/0092-8674(89)90766-6]
12. Ghaderi M, Sabahi F, Sadeghizadeh M, Khanlari Z, Jamaati A, Nasab SDM, et al. Construction of a Minigenome Rescue System for Measles Virus, AIK-c Strain. Iran J Biotech. 2014; 12(2):e18002. [DOI:10.5812/ijb.18002]
13. Ajorloo M., Bamdad T., Gholami A., Azadmanesh K. Assessment the efficiency of the constructed minigenome of rabies virus using PV strain as helper virus. Arch Iran Med. 2016; 19(5):335 - 41.
14. Mostafa Ghaderi, et al,Construction of an eGFP Expression Plasmid under Control of T7 Promoter and IRES Sequence for Assay of T7 RNA Polymerase Activity in Mammalian Cell Lines. Iranian Journal of Cancer Prevention, 2014; 3:137-41.
15. Ben P. H. Peeters, Olav S. de Leeuw, Guus Koch, Arno L. J. Gielkens. Rescue of Newcastle Disease Virus from Cloned cDNA: Evidence that Cleavability of the Fusion Protein Is a Major Determinant for Virulence. 1999, JOURNAL OF VIROLOGY, June, p. 5001-5009. [DOI:10.1128/JVI.73.6.5001-5009.1999] [PMID] [PMCID]
16. Ben Peeters⁎, Olav de Leeuw, A single-plasmid reverse genetics system for the rescue of non-segmented negative-strand RNA viruses from cloned full-length cDNA, Journal of Virological Methods 248 (2017) 187-190. [DOI:10.1016/j.jviromet.2017.07.008] [PMID]
17. Ginés Ávila-Pérez, Aitor Nogales, Verónica Martín, Fernando Almazán and Luis Martínez-Sobrido, Reverse Genetic Approaches for the Generation of Recombinant Zika Virus. 2018, Viruses, 10, 597. [DOI:10.3390/v10110597] [PMID] [PMCID]
18. Naoto Ito, Mutsuyo Takayama-Ito, Kentaro Yamada, Junji Hosokawa, Makoto Sugiyama, and Nobuyuki Minamoto, Improved Recovery of Rabies Virus from Cloned cDNA Using a Vaccinia Virus-Free Reverse Genetics System. 2003, Microbiol. Immunol. 47(8), 613-617. [DOI:10.1111/j.1348-0421.2003.tb03424.x] [PMID]
19. CHRISTOPHE PREHAUD, PATRICE COULON, FLORENCE LAFAY, CHANTAL THIERS, and ANNE FLAMAND. Antigenic Site II of the Rabies Virus Glycoprotein: Structure and Role in Viral Virulence. 1988, JOURNAL OF VIROLOGY, Jan., p. 1-7. [DOI:10.1128/JVI.62.1.1-7.1988] [PMID] [PMCID]
20. Fletcher MA. Hessel L., Plotkin SA. Human diploid cell strains (HDCS) viral vaccines. Dev Biol Stand. 1998; 93:97-107.
21. Milosz Faber, Marie-Luise Faber, Amy Papaneri, and et al. A Single Amino Acid Change in Rabies Virus Glycoprotein Increases Virus Spread and Enhances Virus Pathogenicity. 2005, JOURNAL OF VIROLOGY, Nov., p. 14141-14148. [DOI:10.1128/JVI.79.22.14141-14148.2005] [PMID] [PMCID]
22. Milosz Faber, Marie-Luise Faber, Amy Papaneri, and et al. A Single Amino Acid Change in Rabies Virus Glycoprotein Increases Virus Spread and Enhances Virus Pathogenicity. 2005, JOURNAL OF VIROLOGY, Nov., p. 14141-14148. [DOI:10.1128/JVI.79.22.14141-14148.2005] [PMID] [PMCID]
23. Lafon M (1), Bourhy H, Sureau P. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice. Vaccine. 1988 Aug; 6(4): 362-8. [DOI:10.1016/0264-410X(88)90184-3]
24. Bunschoten H(1), Gore M, Claassen IJ, Uytdehaag FG, Dietzschold B, Wunner WH, Osterhaus AD. Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J Gen Virol. 1989 Feb; 70 (Pt 2):291-8. [DOI:10.1099/0022-1317-70-2-291] [PMID]
25. Fekadu M, Shaddock JH, Ekström J, Osterhaus A, Sanderlin DW, Sundquist B, Morein B. An immune stimulating complex (ISCOM) subunit rabies vaccine protects dogs and mice against street rabies challenge. Vaccine. 1992; 10(3):192-7. [DOI:10.1016/0264-410X(92)90011-8]
26. Okoh AE, Umoh JU, Ezeokoli CD, Addo PB. Vaccination challenge studies with variants of street rabies virus isolated in Nigeria. Vaccine. 1988 Feb; 6(1): 19-24. [DOI:10.1016/0264-410X(88)90008-4]
27. Renato Mancini Astray, Soraia Attie Calil Jorge, Carlos Augusto Pereira. Rabies vaccine development by expression of recombinant viral glycoprotein. 2016, Arch Virol.
28. Mayner RE, Needy CF. Evaluation of the single radial-immunodiffusion assay for measuring the glycoprotein content of rabies vaccines. J Biol Stand. 1987 Jan; 15(1):1-10. [DOI:10.1016/0092-1157(87)90011-4]
29. Lyng J, Bentzon MW, Ferguson M, Fitzgerald EA. Rabies vaccine standardization: International Collaborative Study for the Characterization of the fifth International Standard for Rabies Vaccine. Biologicals. 1992 Dec; 20(4): 301-13. [DOI:10.1016/S1045-1056(05)80051-X]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc